Background: Cerebral ischemia causes a strong inflammatory response. Neumentix is a
dietary supplement containing 14.9% rosmarinic acid and 29.9% total phenolic content, which has
been proved to be beneficial against inflammatory response. Therefore, Neumentix’s effect on
anti-inflammatory and blood brain barrier (BBB) disruption in transient middle cerebral artery occlusion
(tMCAO) model mice is investigated in this study.
Methods: After the pretreatment of vehicle or Neumentix 134 mg/kg/d, intraperitoneal injection
(i.p.) (containing rosmarinic acid 20 mg/kg/d) for 14 days, mice were subjected to tMCAO for
60 min and kept receiving vehicle or Neumentix daily 5 days afterward.
Results: Neumentix treatment ameliorated neurobehavioral impairment in the corner test (5d after
tMCAO, **P<0.01), reduced infarct volume (#P<0.05), suppressed expression of ionized calciumbinding
adapter molecule-1 (Iba-1), tumor necrosis factor alpha (TNF-α) and monocyte chemoattractant
protein-1 (MCP-1) (###P<0.001), and improved the integrity of BBB (§P<0.05) at 5 days
Conclusion: The present study provided an evidence of Neumentix’s anti-inflammatory and neuroprotection
effect against BBB disruption on experimental tMCAO model mice, suggesting that
Neumentix could be a potential therapeutic agent for stroke.